Stanislav Plutizki, PhD
Prior to co-founding and working for GeneQuine, Dr. Plutizki was international medical manager at the regulatory and global medical marketing department at Berlin Chemie AG (Menarini Group), Berlin, Germany, where he was responsible for medical and scientific management of a large product portfolio.
Dr. Plutizki was involved in the registration processes of new products in more than 30 countries (EU, CIS, Asia), dossier management and labelling. Through close collaboration with the marketing department at Berlin Chemie, he was involved in activities for marketed products and new product launches in international markets. Dr. Plutizki also supported the business development department by performing medical and scientific due diligence of new products for potential in-licensing.
Dr. Plutizki received his PhD from the Gutenberg University Mainz, Germany, where he developed and studied a new class of small molecule inhibitors, called Moguntinones, for cancer treatment, resulting in several patents. He is a licensed pharmacist and a pharmacy graduate of the Goethe University in Frankfurt, Germany.